Interestingly, the risk-conferring genotype detected here was different from the one observed earlier by Dhaenens et al. [5] for AD and from what we have seen with regard to the influence of the KLC1 rs8702 polymorphism on cerebrospinal fluid biomarkers of AD [18]. This evidence concerns the gene KLC1 and Alzheimer disease.